Liver resection for intermediate hepatocellular carcinoma

Yi, Peng; Zhang, Ming; Zhao, Jianming; Xu, Mingqing

doi:10.4254/wjh.v8.i14.607

Cited by 13 publications

(6 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCLC classification divides HCC into five stages (0, A, B, C and D) based on pre‐established prognostic variables, and allocates therapies according to treatment‐related status. The BCLC classification has been used as the most common guide for HCC treatment decisions and is endorsed by many guidelines. About 20 per cent of patients with HCC are classified as having BCLC‐B (intermediate stage) HCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Kim

Ahn

Hong

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, the role of liver resection in BCLC‐B HCC was reviewed and showed clear survival benefits for liver resection compared with TACE. However, most of the studies included in this review had several weak points.…”

Section: Discussionmentioning

confidence: 99%

Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Kim

Ahn

Hong

et al. 2017

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…International variation in conditional five-year survival from HCC is likely to reflect the impact of variation in treatment for earlier-stage disease better than variation in five-year survival estimates that include the first year, because many patients with advanced-stage disease will have died in the first year after diagnosis. It may also reflect variation in treatment for localised and early-stage disease, through wider access to surgery (38,43,44), including liver transplantation (45,46), better patient selection (47)(48)(49) and clinical experience (50)(51)(52). Almost all these studies were done in Taiwan or the US.…”

Section: Discussionmentioning

confidence: 99%

Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 countries (CONCORD-2)

Bannon¹,

Carlo²,

Harewood³

et al. 2019

Ann Cancer Epidemiol

View full text Add to dashboard Cite

Background: Primary liver cancer is the fifth most common cancer worldwide , and the second most common cause of death from cancer, with an estimated 841,100 new cases and 781,500 deaths each year. Hepatocellular carcinoma (HCC) accounts for 60-80% of cases, and cholangiocarcinoma 10-40%. We examined global trends in survival for both these sub-types of liver cancer, by country, age, sex and calendar period. Methods: Data on 1,005,032 adults (aged 15-99 years) diagnosed with a primary, invasive malignant neoplasm of the liver or intrahepatic bile ducts between 1995 and 2009 were provided by 243 populationbased cancer registries in 60 countries. Analysis was restricted to patients for whom the diagnosis of a primary malignancy had been confirmed by histological or cytological examination, or assignation of a specific morphology code, and to registries from which survival estimates were considered reliable. We estimated both five-year net survival and conditional five-year net survival, for patients who survived to the first anniversary of diagnosis. Funnel plots were used to examine international variation in survival and variation by age and morphology. Results: Data on 578,740 patients from 187 registries in 36 countries were included after quality control. For patients diagnosed during 2004-2009, the pooled estimate of age-standardised five-year net survival for liver cancer was 14.8% (range, 4.4-23.7%), higher than for patients diagnosed during 1995-2000 (11.0%). Survival for patients diagnosed with HCC during 2004-2009 (pooled estimate 17.4%, range 7.7-25.5%) was higher than for those with cholangiocarcinoma (8.4%, range 3.7-16.0%). Survival for patients diagnosed during 2004-2009 was higher in Canada, Italy, Japan, Taiwan and Korea (21.2-23.7%) than the pooled

show abstract

“…In recent years, local-regional therapies, including transarterial chemoembolization (TACE) and radiofrequency ablation have been regarded as optimal therapies for HCC patients. 9 , 10 TACE has been generally recommended as the standard palliative therapeutic regimen by guidelines and expert consensus for unresectable HCC. 11 - 13 However, comparing with the other treatment options, such as chemotherapy, molecular targeted therapy or immunotherapy, TACE displays limited benefits.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study

Guo

Song

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective: This study aimed to explore the efficacy and safety of using transarterial chemoembolization (TACE) combined with anlotinib in patients with unresectable hepatocellular carcinoma, compared with TACE alone. Methods: This was a single-center study, retrospectively recruited 82 unresectable HCC patients who received either TACE alone (TA group; n = 46) or TACE combined with anlotinib (TC group; n = 36) between Jan 2018 and Jan 2019. The primary outcomes were progression-free survival (PFS) and overall survival (OS). While the secondary outcomes were the objective response rate (ORR), the disease control rate (DCR), and main complications. Log-rank test and Kaplan–Meier method was used to calculate the survival difference. All statistical tests were 2-sided and P value <0.05 were taken as statistically significant. Results: Patients in TC group had a significant higher PFS than those in TA group (7.35 months vs. 5.54 months, p = 0.035). Although 3-month survival rate in the 2 groups was not statistically different (97.2% vs. 93.5%, p = 0.627), the survival rate at 6 months and 1 year were strongly higher in TC group (83.3% vs. 56.5%, p = 0.016; 66.7% vs. 19.6%, respectively, p < 0.05). Furthermore, there was a significantly higher ORR in TC group, while no statistical difference existed in DCR. Neither treatment-related mortality nor grade 4 adverse events (AEs) occurred. However, 2 patients in TC group had grade 3 AEs (one suffered with erythra, and the other with hand-foot-skin reaction), which disappeared after prompt treatment. Conclusion: TACE combined with anlotinib is safe and may improve outcomes for unresectable HCC patients comparing with TACE alone. Randomized controlled trials are warranted to further evaluate treatment effects of anlotinib in HCC.

show abstract

Liver resection for intermediate hepatocellular carcinoma

Abstract: MINIREVIEWSSubmit a

Cited by 13 publications

References 57 publications

Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Survival trends for primary liver cancer, 1995–2009: analysis of individual data for 578,740 patients from 187 population-based registries in 36 countries (CONCORD-2)

Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study

Contact Info

Product

Resources

About